Trending...
- TEÓNA Releases New Single "What I Want" — A Bold Anthem for Every Woman Who Once Had a Bad Love
- The CRE Finance Council Announces New Chairs for Industry Forums
- MetaSwap Exchange Rolls Out Multilingual Access System to Enhance Global User Experience
NEW YORK - Nyenta -- Lifenome Inc., a global leader in AI-driven precision health and longevity technologies, and Pathomics Health, Southeast Asia's rising innovator in molecular diagnostics and personalized health, have announced a strategic partnership to jointly accelerate access to cutting-edge longevity-based solutions across Southeast Asia.
This partnership marks a significant milestone in the evolution of personalized medicine in the region, combining Lifenome's advanced genomics and epigenetics-driven longevity platform with Pathomics' accredited clinical infrastructure and regional diagnostic reach.
We're thrilled to partner with Pathomics, whose regional expertise and diagnostic excellence make them an ideal ally in bringing our vision of personalized, preventive, and longevity-enhancing health solutions to Southeast Asia," said Dr. Ali Mostashari, CEO and Co-Founder of Lifenome. "Together, we are enabling a shift from reactive to proactive health in one of the world's most dynamic and diverse health markets.
Pathomics Health, headquartered in Singapore, operates licensed, CAP-accredited molecular laboratories and offers a growing suite of genomic and proteomic diagnostics. The company has expanded rapidly through partnerships in Malaysia, Thailand, the Philippines, and Mongolia, and is recognized for bringing clinically meaningful innovation to underserved health areas such as early cancer detection, diabetes-related kidney decline, and neurodegenerative risk profiling.
More on Nyenta.com
Lifenome's science-backed longevity and precision health platform is an ideal fit with our diagnostic capabilities and Southeast Asia's unmet demand for prevention-first healthcare," said Dr. Ron Tan, CEO of Pathomics Health.
The precision health market in Southeast Asia is poised for rapid growth. According to industry estimates, the ASEAN precision medicine market is projected to exceed USD $14.5 billion by 2030, driven by rising chronic disease burdens, increasing health literacy, and government investments in genomic initiatives. Countries such as Singapore, Malaysia, and Thailand are emerging as hubs for personalized medicine, while Indonesia and the Philippines represent untapped markets with vast population bases.
This partnership will initially focus on co-launching a suite of longevity and wellness panels, polygenic risk assessments, and nutrigenomics services, leveraging Lifenome's validated algorithms trained on over 900,000 individuals globally. These will be locally adapted and clinically integrated through Pathomics' regional lab network and clinical partnerships. Additional applications in women's health, cardiovascular risk reduction, and metabolic optimization are also in development.
More on Nyenta.com
About Lifenome
LifeNome (https://www.lifenome.com/) is the world's first B2B(2C) Longevity Operating System (Longevity OS™), an AI-powered platform that integrates multi-omics data (genomics, epigenetics, microbiome, wearable data, and biomarkers) to deliver personalized health, wellness, and longevity solutions at scale.
About Pathomics Health
Pathomics Health (https://pathomicshealth.com/) is a Singapore-based diagnostics and precision medicine company focused on molecular testing and personalized health applications in oncology, cardiometabolic diseases, infectious diseases, and neurological conditions. With CAP accreditation and an expanding footprint in ASEAN countries, Pathomics is redefining health access through innovation.
This partnership marks a significant milestone in the evolution of personalized medicine in the region, combining Lifenome's advanced genomics and epigenetics-driven longevity platform with Pathomics' accredited clinical infrastructure and regional diagnostic reach.
We're thrilled to partner with Pathomics, whose regional expertise and diagnostic excellence make them an ideal ally in bringing our vision of personalized, preventive, and longevity-enhancing health solutions to Southeast Asia," said Dr. Ali Mostashari, CEO and Co-Founder of Lifenome. "Together, we are enabling a shift from reactive to proactive health in one of the world's most dynamic and diverse health markets.
Pathomics Health, headquartered in Singapore, operates licensed, CAP-accredited molecular laboratories and offers a growing suite of genomic and proteomic diagnostics. The company has expanded rapidly through partnerships in Malaysia, Thailand, the Philippines, and Mongolia, and is recognized for bringing clinically meaningful innovation to underserved health areas such as early cancer detection, diabetes-related kidney decline, and neurodegenerative risk profiling.
More on Nyenta.com
- Female Motorsports Sponsorship & Expansion; Acquisition Agreement of UAE-Based Sports Incubator by Online Lottery & Sports Game Provider: Lottery.com
- SupplyHouse Named One of Fortune's Best Workplaces in New York in 2025
- Kosinima, Inc. Unveils Third Cohort Of Grantees, Expanding Global Footprint For Black Filmmakers
- Global Court Momentum Builds Against Forced Psychiatry; CCHR Urges U.S. Reform
- ¡Buenos Días, USA!AIRE Radio Networks Announces the Syndication of El Show de Raúl Brindis
Lifenome's science-backed longevity and precision health platform is an ideal fit with our diagnostic capabilities and Southeast Asia's unmet demand for prevention-first healthcare," said Dr. Ron Tan, CEO of Pathomics Health.
The precision health market in Southeast Asia is poised for rapid growth. According to industry estimates, the ASEAN precision medicine market is projected to exceed USD $14.5 billion by 2030, driven by rising chronic disease burdens, increasing health literacy, and government investments in genomic initiatives. Countries such as Singapore, Malaysia, and Thailand are emerging as hubs for personalized medicine, while Indonesia and the Philippines represent untapped markets with vast population bases.
This partnership will initially focus on co-launching a suite of longevity and wellness panels, polygenic risk assessments, and nutrigenomics services, leveraging Lifenome's validated algorithms trained on over 900,000 individuals globally. These will be locally adapted and clinically integrated through Pathomics' regional lab network and clinical partnerships. Additional applications in women's health, cardiovascular risk reduction, and metabolic optimization are also in development.
More on Nyenta.com
- Integris Composites Joins Paris Air Show at USA Pavilion
- Cheryl Hines' Trailer PROWLING to Sardinia
- Top 5 Myths About Dental Implants – Debunked by a Webster, NY Dentist
- Honoring Black History, Culture, and Community in Fall River
- Token-Operated Sake Service Opens at Tobu Nikko Station
About Lifenome
LifeNome (https://www.lifenome.com/) is the world's first B2B(2C) Longevity Operating System (Longevity OS™), an AI-powered platform that integrates multi-omics data (genomics, epigenetics, microbiome, wearable data, and biomarkers) to deliver personalized health, wellness, and longevity solutions at scale.
About Pathomics Health
Pathomics Health (https://pathomicshealth.com/) is a Singapore-based diagnostics and precision medicine company focused on molecular testing and personalized health applications in oncology, cardiometabolic diseases, infectious diseases, and neurological conditions. With CAP accreditation and an expanding footprint in ASEAN countries, Pathomics is redefining health access through innovation.
Source: Lifenome Inc
Filed Under: Health
0 Comments
Latest on Nyenta.com
- United States Congressional Candidate Peter Coe Verbica Unveils 25-Point Federal Plan to Help Make California Affordable Again
- D8Averse Launches D8Acapture: Disruptive Mobile-First App Transforms Utility Pole Data Collection
- Experience Trembling Firsthand with the New AgeMan® Tremor Simulator
- "Keeping Her Dream Alive" – A Free Virtual Celebration of Blood Cancer Survivors - June 25, 2025
- Westchester Network for Professionals Launches Mid-Year Reset:Membership Drive to Help Professionals
- "Brazilian Morning: The Yin Mix" – A Sonic Tapestry of Healing and Heritage
- Ameritas announces newly elected officers
- Mauro Schnaidman named as Managing Director in Miami, Florida
- Continued Streak of Recognitions with Multiple Chambers and Partners Rankings
- Anern Shines at SOLAR AFRICA Kenya with Solar Lithium Battery Storage Technology
- Last Call - Submit Your Proposal for the 2025 OpenSSL Conference in Prague
- Robert Michael & Co. Launches New Real Estate Website to Serve Central Florida Homebuyers and Sellers
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Laser Photonics Corporation - LASE
- IFFA 2025 Shines Bright as Mukesh Modi Welcomes Rio Rocket and Award Winner Lulu Lopez
- Legal-Bay Pre-Settlement Funding Investigates Emerging Lawsuits Against Depo-Provera Birth Control
- MetaSwap Exchange Rolls Out Multilingual Access System to Enhance Global User Experience
- Kemeny, Ramp & Renaud Expands Legal Team with Attorney Baruch Kraut
- Rochester: 'What Justice Means to Me': Students recognized for winning J.U.S.T. L.A.W. essay contest
- Rochester: City Opens First Dedicated Pickleball Courts in Maplewood Park
- Rochester: International Plaza to Host Latin American and Caribbean-Themed Father's Day Celebration Sunday